Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Sci Rep ; 14(1): 10477, 2024 05 07.
Artigo em Inglês | MEDLINE | ID: mdl-38714743

RESUMO

Endothelial glycocalyx (eGC) covers the inner surface of the vessels and plays a role in vascular homeostasis. Syndecan is considered the "backbone" of this structure. Several studies have shown eGC shedding in sepsis and its involvement in organ dysfunction. Matrix metalloproteinases (MMP) contribute to eGC shedding through their ability for syndecan-1 cleavage. This study aimed to investigate if doxycycline, a potent MMP inhibitor, could protect against eGC shedding in lipopolysaccharide (LPS)-induced sepsis and if it could interrupt the vascular hyperpermeability, neutrophil transmigration, and microvascular impairment. Rats that received pretreatment with doxycycline before LPS displayed ultrastructural preservation of the eGC observed using transmission electronic microscopy of the lung and heart. In addition, these animals exhibited lower serum syndecan-1 levels, a biomarker of eGC injury, and lower perfused boundary region (PBR) in the mesenteric video capillaroscopy, which is inversely related to the eGC thickness compared with rats that only received LPS. Furthermore, this study revealed that doxycycline decreased sepsis-related vascular hyperpermeability in the lung and heart, reduced neutrophil transmigration in the peritoneal lavage and inside the lungs, and improved some microvascular parameters. These findings suggest that doxycycline protects against LPS-induced eGC shedding, and it could reduce vascular hyperpermeability, neutrophils transmigration, and microvascular impairment.


Assuntos
Doxiciclina , Glicocálix , Lipopolissacarídeos , Sepse , Glicocálix/metabolismo , Glicocálix/efeitos dos fármacos , Animais , Sepse/tratamento farmacológico , Sepse/metabolismo , Doxiciclina/farmacologia , Ratos , Masculino , Permeabilidade Capilar/efeitos dos fármacos , Pulmão/patologia , Pulmão/metabolismo , Pulmão/efeitos dos fármacos , Sindecana-1/metabolismo , Ratos Wistar , Endotélio Vascular/efeitos dos fármacos , Endotélio Vascular/metabolismo , Endotélio Vascular/patologia , Células Endoteliais/efeitos dos fármacos , Células Endoteliais/metabolismo , Neutrófilos/metabolismo , Neutrófilos/efeitos dos fármacos , Inibidores de Metaloproteinases de Matriz/farmacologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...